Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin

The World Health Organization (WHO) has listed moxifloxacin and linezolid among the preferred “Group A” drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB) [1]. Therapeutic drug monitoring (TDM) could potentially optimise MDR-TB therapy, since moxifloxacin and linezolid show large pharmacokinetic variability [1–4]. TDM of moxifloxacin focuses on identifying patients with low drug exposure who are at risk of treatment failure and acquired fluoroquinolone resistance [5, 6]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. van den Elsen has nothing to disclose. Conflict of interest: Dr. Akkerman has nothing to disclose. Conflict of interest: Dr. Jongedijk has nothing to disclose. Conflict of interest: Dr. Wessels has nothing to disclose. Conflict of interest: Dr. Ghimire has nothing to disclose. Conflict of interest: Dr. van der Werf has nothing to disclose. Conflict of interest: Dr. Touw has nothing to disclose. Conflict of interest: Dr. Bolhuis has nothing to disclose. Conflict of interest: Dr. Alffenaar has nothing to disclose.